CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 401-410

  Hertz, Daniel L ^a   Motsinger Reif, Alison A ^a,b   Drobish, Amy ^c   Winham, Stacey J ^b,e   McLeod, Howard L ^a,c,d   Carey, Lisa A ^c,d   Dees, E Claire ^c,d  

^a University of North Carolina at Chapel Hill   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Clinical complete response; CYP2C8*3; Neoadjuvant breast cancer therapy; Paclitaxel; Pharmacogenetics

Indexed keywords

PACLITAXEL; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CYP2C8 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; UNSPECIFIC MONOOXYGENASE;

ABCB1 GENE; ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SIZE; CONTROLLED STUDY; CYP1B1 GENE; CYP2C8 GENE; CYP3A4 GENE; CYP3A5 GENE; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG METABOLISM; DRUG RESPONSE; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; GENE; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; DRUG EFFECT; GENE FREQUENCY; GENETIC ASSOCIATION; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; P-GLYCOPROTEIN; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR BURDEN;

EID: 84863981895     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2054-0     Document Type: Article

References (55)

1. A Henningsson A Sparreboom M Sandström A Freijs R Larsson J Bergh P Nygren MO Karlsson 2003 Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients Eur J Cancer 39 8 1105 1114 12736110 10.1016/S0959-8049(03)00126-6 1:CAS:528:DC%2BD3sXjsVaru74%3D
2. JA Sparano M Wang S Martino V Jones EA Perez T Saphner AC Wolff GW Sledge WC Wood NE Davidson 2008 Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 16 1663 1671 18420499 10.1056/NEJMoa0707056 1:CAS:528:DC%2BD1cXkslCitLk%3D
3. A Di Leo HL Gomez Z Aziz Z Zvirbule J Bines MC Arbushites SF Guerrera M Koehler C Oliva SH Stein LS Williams J Dering RS Finn MF Press 2008 Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer J Clin Oncol 26 34 5544 5552 18955454 10.1200/JCO.2008.16.2578
4. HL McLeod WE Evans 2001 Pharmacogenomics: unlocking the human genome for better drug therapy Annu Rev Pharmacol Toxicol 41 101 121 11264452 10.1146/annurev.pharmtox.41.1.101 1:CAS:528:DC%2BD3MXjsVaqsbg%3D
5. JM Hoskins RM Goldberg P Qu JG Ibrahim HL McLeod 2007 UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters J Natl Cancer Inst 99 17 1290 1295 17728214 10.1093/jnci/djm115 1:CAS:528:DC%2BD2sXhtVWqtbnI
6. Z Hu Q Yu Y Zhao 2010 Dose-dependent association between UGT1A1 28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis Eur J Cancer 46 10 1856 1865 20335017 10.1016/j.ejca.2010.02.049 1:CAS:528:DC%2BC3cXntlajtbk%3D
7. TE Klein RB Altman N Eriksson BF Gage SE Kimmel International Warfarin Pharmacogenetics Consortium, et al. 2009 Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 8 753 764 19228618 10.1056/NEJMoa0809329
8. H Chang SY Rha HC Jeung CK Im SH Noh JJ Kim HC Chung 2010 Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy Oncol Rep 23 1 271 278 19956892 1:CAS:528:DC%2BC3cXoslGnuw%3D%3D
9. H Chang SY Rha H- Jeung C- Im JB Ahn WS Kwon NC Yoo JK Roh HC Chung 2009 Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients Ann Oncol 20 2 272 277 18836089 10.1093/annonc/mdn624 1:STN:280: DC%2BD1M7jtlWlsA%3D%3D
10. H Green P Soderkvist P Rosenberg G Horvath C Peterson 2006 Mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy Clin Cancer Res 12 3 854 859 16467099 10.1158/1078-0432.CCR-05-0950 1:CAS:528:DC%2BD28XhtFeiurc%3D
11. S Leskela C Jara L Leandro-Garcia A Martinez J Garcia-Donas S Hernando A Hurtado JCC Vicario C Montero-Conde I Landa E Lopez-Jimenez A Cascon RL Milne M Robeldo C Rodriguez-Antona 2011 Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity Pharmacogenomics J 11 2 121 129 20212519 10.1038/tpj.2010.13 1:CAS:528:DC%2BC3cXivV2rt7s%3D
12. WP Petros PJ Hopkins S Spruill G Broadwater JJ Vredenburgh OM Colvin WP Peters RB Jones J Hall JR Marks 2005 Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer J Clin Oncol 23 25 6117 6125 16087946 10.1200/JCO.2005.06.075 1:CAS:528:DC%2BD2MXhtVKgtb3F
13. S Marsh G Somlo X Li P Frankel CR King WD Shannon HL McLeod TW Synold 2007 Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer Pharmacogenomics J 7 5 362 365 17224914 10.1038/sj.tpj.6500434 1:CAS:528:DC%2BD2sXhtVOrtLjJ
14. Kroetz DL, Baldwin RM, Owzar K, Jiang C, Zembutsu H, Kubo M, Nakamura Y, Shulman LN, Ratain MJ, Cancer and Leukemia Group B. (2010) Inherited genetic variation in EPHA5, FGD4, and NRDG1 and paclitaxel (P)-induced peripheral neuropathy (PN): results from a genome-wide association study (GWAS) in CALGB 40101. ASCO Meeting Abstracts. 2010 June 14;28(15 Suppl):3021
15. Schneider BP, Li L, Miller K, Flockhart D, Radovich M, Hancock BA, Kassem N, Forourd T, Koller DL, Badve SS, Li Z, Partridge AH, O'Neill AM, Sparano JA, Dang CT, Northfelt DW, Smith ML, Railey E, Sledge GW (2011) Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. ASCO Meeting Abstracts. 2011 June 09;29(15-suppl):1000
16. R Rizzo F Spaggiari M Indelli G Lelli O Baricordi P Rimessi A Ferlini 2010 Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients Breast Cancer Res Treat 124 2 593 598 20632082 10.1007/s10549-010-1034-5 1:CAS:528:DC%2BC3cXht12qur3M
17. TM Sissung K Mross SM Steinberg D Behringer WD Figg A Sparreboom S Mielke 2006 Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia Eur J Cancer 42 17 2893 2896 16950614 10.1016/j.ejca.2006.06.017 1:CAS:528:DC%2BD28XhtFOjt7fK
18. T Sørlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey T Thorsen H Quist JC Matese PO Brown D Botstein PE Lenning A Borresen-Dale 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 10869 10874 11553815 10.1073/pnas.191367098
19. JW Eley HA Hill VW Chen DF Austin MN Wesley HB Muss RS Greenberg RJ Coates P Correa CK Redmond 1994 Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study JAMA 272 12 947 954 8084062 10.1001/jama.1994.03520120057031 1:STN:280:DyaK2czms1Sguw%3D%3D
20. EA Eisenhauer P Therasse J Bogaerts LH Schwartz D Sargent R Ford J Dancey S Arbuck S Gwyther M Mooney L Rubinstein L Shankar L Dodd R Kaplan D Lacombe J Verweij 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 228 247 19097774 10.1016/j.ejca.2008. 10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D
21. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2010 June 14, 2010
22. S Marsh CR King AA Garsa HL McLeod 2005 Pyrosequencing of clinically relevant polymorphisms Methods Mol Biol 311 97 114 16100402 1:CAS:528: DC%2BD2MXhtVekt7fL
23. CM Rose S Marsh MM Ameyaw HL McLeod 2003 Pharmacogenetic analysis of clinically relevant genetic polymorphisms Methods Mol Med 85 225 237 12710211 1:CAS:528:DC%2BD3sXjt1yhsbs%3D
24. M Stephens P Donnelly 2003 A comparison of bayesian methods for haplotype reconstruction from population genotype data Am J Hum Genet 73 5 1162 1169 14574645 10.1086/379378 1:CAS:528:DC%2BD3sXptVGnsL4%3D
25. M Stephens NJ Smith P Donnelly 2001 A new statistical method for haplotype reconstruction from population data Am J Hum Genet 68 4 978 989 11254454 10.1086/319501 1:STN:280:DC%2BD3M3kslWgsA%3D%3D
26. SD Baker J Verweij GA Cusatis R van Schaik S Marsh SJ Orwick RM Franke S Hu EG Schuetz V Lamba WA Messersmith AC Wolff MA Carducci A Sparreboom 2008 Pharmacogenetic pathway analysis of docetaxel elimination Clin Pharmacol Ther 85 2 155 163 18509327 10.1038/clpt.2008.95
27. TM Sissung CE Baum J Deeken DK Price J Aragon-Ching SM Steinberg W Dahut A Sparreboom WD Figg 2008 ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel Clin Cancer Res 14 14 4543 4549 18628469 10.1158/1078-0432.CCR- 07-4230 1:CAS:528:DC%2BD1cXosFGitLc%3D
28. JS Barnholtz-Sloan M de Andrade R Chakraborty 2001 The impact of population admixture on traditional linkage analysis Ethn Dis 11 3 519 531 11572417 1:STN:280:DC%2BD3MrisVyluw%3D%3D
29. A Garsa H McLeod S Marsh 2005 CYP3A4 and CYP3A5 genotyping by pyrosequencing BMC Med Genet 6 1 19 15882469 10.1186/1471-2350-6-19
30. International HapMap Consortium 2003 The international HapMap project Nature 426 6968 789 796 10.1038/nature02168
31. NCBI (2010) NCBI entrez SNP database. Available from: http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp. Accessed Oct 05, 2008
32. WG Cance LA Carey BF Calvo C Sartor L Sawyer DT Moore J Rosenman DW Ollila M Graham 2002 Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival Ann Surg 236 3 295 302 12192316 10.1097/00000658-200209000-00006 Discussion: 302-303
33. LA Carey R Metzger EC Dees F Collichio CI Sartor DW Ollila N Klauber-DeMore J Halle L Sawyer DT Moore ML Graham 2005 American Joint Committee on Cancer Tumor-Node-Metastasis stage after neoadjuvant chemotherapy and breast cancer outcome J Natl Cancer Inst 97 15 1137 1142 16077072 10.1093/jnci/dji206
34. B Fisher J Bryant N Wolmark E Mamounas A Brown ER Fisher DL Wickerham M Begovic A DeCillis A Robidoux RG Margolese AB Cruz JL Hoehn AW Lees NV Dimitrov HD Bear 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 8 2672 2685 9704717 1:CAS:528: DyaK1cXlsFCgurg%3D
35. S Zheng BL Zhang RZ Zhang JL Yang SM Zou LY Xue W Luo YL Yuan N Lu 2010 Differences between clinical response and pathologic response of breast cancer after neoadjuvant chemotherapy Zhonghua Bing Li Xue Za Zhi 39 11 734 738 21215162 in Chinese
36. S Marsh J Paul CR King G Gifford HL McLeod R Brown 2007 Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer J Clin Oncol 25 29 4528 4535 17925548 10.1200/JCO.2006.10.4752 1:CAS:528:DC%2BD2sXht1yhsr7P
37. TK Bergmann H Gréen C Brasch-Andersen M Mirza J Herrstedt B Hølund A du Bois P Damkier W Vach K Brosen C Peterson 2011 Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer Eur J Clin Pharmacol 67 7 693 700 21327421 10.1007/s00228-011-1007-6 1:CAS:528:DC%2BC3MXnsVSqsro%3D
38. A Sparreboom MT Huizing JJB Boesen WJ Nooijen JH Beijnen OV Tellingen 1995 Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces Cancer Chemother Pharmacol 36 4 299 304 7628049 10.1007/BF00689047 1:CAS:528:DyaK2MXnsFShtLo%3D
39. S Mielke A Sparreboom SM Steinberg H Gelderblom C Unger D Behringer K Mross 2005 Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer Clin Cancer Res 11 13 4843 4850 16000582 10.1158/1078-0432.CCR-05-0298 1:CAS:528:DC%2BD2MXlvVGgs7w%3D
40. ME de Jonge HJGD van den Bongard ADR Huitema RAA Mathôt H Rosing P Baas N van Zandwijk JH Beijnen JHM Schellens 2004 Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer Clin Cancer Res 10 7 2237 2244 15073098 10.1158/1078-0432.CCR-03-0060
41. JMA van Gerven JWB Moll MJ van den Bent M Bontenbal MEL van der Burg J Verweij CJ Vecht 1994 Paclitaxel (taxol) induces cumulative mild neurotoxicity Eur J Cancer 30 8 1074 1077 10.1016/0959-8049(94)90459-6
42. SE Rowbotham AV Boddy CPF Redfern GJ Veal AK Daly 2010 Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation Drug Metab Dispos 38 8 1261 1266 20421446 10.1124/dmd.109.030866 1:CAS:528:DC%2BC3cXhtVWktrvE
43. A Soyama Y Saito N Hanioka N Murayama O Nakajima N Katori S Ishida S Kimie S Ozawa J Sawada 2001 Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism Biol Pharm Bull 24 12 1427 1430 11767116 10.1248/bpb.24.1427 1:CAS:528:DC%2BD3MXosl2rsrc%3D
44. N Bahadur JBS Leathart E Mutch D Steimel-Crespi SA Dunn R Gilissen JV Houdt J Hendrickx G Mannens H Bohets FM Williams M Armstrong CL Crespi AK Daly 2002 CYP2C8 polymorphisms in caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes Biochem Pharmacol 64 11 1579 1589 12429347 10.1016/S0006-2952(02)01354-0 1:CAS:528:DC%2BD38XosFKls7o%3D
45. D Dai DC Zeldin JA Blaisdell B Chanas SJ Coulter BI Ghanayem JA Goldstein 2001 Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid Pharmacogenetics 11 7 597 607 11668219 10.1097/00008571-200110000-00006 1:CAS:528:DC%2BD3MXotFWlt7c%3D
46. TK Bergmann C Brasch-Andersen H Green M Mirza RS Pedersen F Nielsen K Skougaard J Wihl N Keldsen P Damkier LE Friberg C Peterson W Vach MO Karlsson K Brosen 2011 Impact of CYP2C8*3 on paclitaxel clearance: A population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer Pharmacogenomics J 11 2 113 120 20368717 10.1038/tpj.2010.19 1:CAS:528:DC%2BC3cXkt1aqs7g%3D
47. Y Gao D Liu H Wang J Zhu C Chen 2010 Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions Xenobiotica 40 7 467 475 20459297 10.3109/00498254.2010.487163 1:CAS:528:DC%2BC3cXnt12gtr0%3D
48. WC Speed SP Kang DP Tuck LN Harris KK Kidd 2009 Global variation in CYP2C8-CYP2C9 functional haplotypes Pharmacogenomics J 9 4 283 290 19381162 10.1038/tpj.2009.10 1:CAS:528:DC%2BD1MXkslOgsL0%3D
49. AD Seidman D Berry C Cirrincione L Harris H Muss PK Marcom G Gipson H Burstein D Lake CL Shapiro P Ungaro L Norton E Winer C Hudis 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840 J Clin Oncol 26 10 1642 1649 18375893 10.1200/JCO.2007.11.6699 1:CAS:528:DC%2BD1cXltlWhsr0%3D
50. A Henningsson S Marsh WJ Loos MO Karlsson A Garsa K Mross S Mielke L Vigano A Locatelli J Verweij A Sparreboom HL McLeod 2005 Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel Clin Cancer Res 11 22 8097 8104 16299241 10.1158/1078-0432.CCR-05-1152 1:CAS:528:DC%2BD2MXht1entr%2FF
51. DR Gandara T Kawaguchi J Crowley J Moon K Furuse M Kawahara S Teramukai Y Ohe K Kubota ST Williamsoon O Gautschi HJ Lenz HL McLeod PN Lara CA Coltman M Fukuoka N Saijo M Fukushima PC Mack 2009 Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics J Clin Oncol 27 21 3540 3546 19470925 10.1200/JCO.2008.20.8793 1:CAS:528:DC%2BD1MXhtVSqtLjJ
52. B Bournique A Lemarié 2002 Docetaxel (taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme Drug Metab Dispos 30 11 1149 1152 12386117 10.1124/dmd.30.11.1149 1:CAS:528:DC%2BD38XotFyktbc%3D
53. TM Sissung R Danesi DK Price SM Steinberg R de Wit M Zahid N Gaikwad E Cavalieri WL Dahut DL Sackett WD Figg A Sparreboom 2008 Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel Mol Cancer Ther 7 1 19 26 18187806 10.1158/1535-7163.MCT-07-0557 1:CAS:528:DC%2BD1cXmsVygsg%3D%3D
54. I Pastina E Giovannetti A Chioni TM Sissung F Crea C Orlandini DK Price C Cianci WD Figg S Ricci R Danesi 2010 Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in castration-resistant prostate cancer (CRPC) patients BMC Cancer 27 10 511 10.1186/1471-2407-10-511
55. WD Figg H Li T Sissung A Retter S Wu JL Gulley P Arlen JJ Wright H Parnes K Fedenko L Latham SM Steinberg E Jones C Chen W Dahut 2007 Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer BJU Int 99 5 1047 1055 17437439 10.1111/j.1464-410X.2007.06763.x 1:CAS:528:DC%2BD2sXmvVaqsLk%3D